EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders

Oslo, Norway, 5 February 2026. Reference is made to the stock exchange announcement by EXACT Therapeutics AS (the "Company", Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, earlier today on 5 February 2026, confirming that GE Medical Holdings AB (“GEMH”) will exercise of all of its 26,973,169 warrants.

The Company is pleased to announce that the following major shareholders and primary insiders today have confirmed that they will exercise all of their warrants, as follows:

• Investinor Direkte AS, a close associate of board member Ann-Tove Kongsnes: 4,875,920 warrants • Helene Sundt AS, a close associate of board member Leiv Askvig: 2,050,577 warrants • Sundt AS, a close associate of board member Leiv Askvig: 420,396 warrants • Basen Kapital AS, a close associate of board member Leiv Askvig: 87,107 warrants • Anders Wold, chair of the Company: 69,685 warrants • Canica AS: 3,273,334 warrants

The exercise of the above-mentioned warrants, combined with the warrants exercised by GEMH, accounts for 75% of the total warrants issued in conjunction with the private placement completed in December 2024, corresponding to gross proceeds of NOK 46 million.

The remaining warrants holders may exercise their warrants within 21 February 2026. Updates on the warrant exercise will follow in due course.

As soon as the Company has confirmation from the remaining warrants holders on whether they will exercise their warrants, the Company will call for an extraordinary general meeting to ensure that the relevant number of new shares are issued.

Further, please find attached an updated corporate presentation which may also be found in the Investors section of the Company’s webpage.

Please see the attached PDMR notification in accordance with Regulation EU 596/2014 (MAR) article 19 for further details.

About EXACT Therapeutics: EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here:www.exact-tx.com

For further information, please contact: Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com